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PRODH maps to 22q11 in the region deleted in the velocardiofacial syndrome/DiGeorge syndrome (VCFS/DGS)
and encodes proline oxidase (POX), a mitochondrial inner-membrane enzyme that catalyzes the first step in the
proline degradation pathway. At least 16 PRODH missense mutations have been identified in studies of type I
hyperprolinemia (HPI) and schizophrenia, 10 of which are present at polymorphic frequencies. The functional
consequences of these missense mutations have been inferred by evolutionary conservation, but none have been
tested directly. Here, we report the effects of these mutations on POX activity. We find that four alleles (R185Q,
L289M, A455S, and A472T) result in mild (!30%), six (Q19P, A167V, R185W, D426N, V427M, and R431H) in
moderate (30%–70%), and five (P406L, L441P, R453C, T466M, and Q521E) in severe (170%) reduction in POX
activity, whereas one (Q521R) increases POX activity. The POX encoded by one severe allele (T466M) shows in
vitro responsiveness to high cofactor (flavin adenine dinucleotide) concentrations. Although there is limited infor-
mation on plasma proline levels in individuals of known PRODH genotype, extant data suggest that severe hy-
perprolinemia (1800 mM) occurs in individuals with large deletions and/or PRODH missense mutations with the
most-severe effect on function (L441P and R453C), whereas modest hyperprolinemia (300–500 mM) is associated
with PRODH alleles with a moderate reduction in activity. Interestingly, three of the four alleles associated with
or found in schizophrenia (V427M, L441P, and R453C) resulted in severe reduction of POX activity and hyper-
prolinemia. These observations plus the high degree of polymorphism at the PRODH locus are consistent with the
hypothesis that reduction in POX function is a risk factor for schizophrenia.
Introduction
The PRODH gene comprises 15 exons that span 23.77
kb, located at 17.3 Mb (National Center for Biotech-
nology Information build 34) in 22q11, near the centro-
meric end of the region typically deleted in the velo-
cardiofacial syndrome/DiGeorge syndrome (VCFS/DGS)
(McDermid and Morrow 2002). A PRODH pseudogene
(WPRODH) located 1.4 Mb telomeric on 22q at 18.7
Mb has 195% sequence identity with PRODH but has
an internal deletion that removes a 13.1-kb segment con-
taining exons 2 through the 5′ half of exon 7, along with
the intervening introns (Liu et al. 2002a, 2002b; Mc-
Dermid and Morrow 2002; Williams et al. 2003b) (fig.
1). WPRODH has accumulated several missense muta-
tions that, in some instances, have been transferred
to PRODH, apparently by gene conversion (Liu et al.
2002b).
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PRODH encodes proline oxidase (POX), a mitochon-
drial inner-membrane enzyme—expressed in kidney,
liver, and brain—that catalyzes the conversion of proline
to D1-pyrroline-5-carboxylate (P5C) by use of flavin ad-
enine dinucleotide (FAD) as a cofactor (fig. 2). P5C has
three possible metabolic fates: oxidation to glutamate
in a reaction catalyzed by P5C dehydrogenase, trans-
amination to ornithine in a reaction catalyzed by or-
nithine aminotransferase, or reduction back to proline
in a reaction catalyzed by P5C reductase by use of either
nicotinamide adenine dinucleotide phosphate or nico-
tinamide adenine dinucleotide as cofactor. The latter
reaction, coupled with POX, forms a cycle of proline
synthesis and degradation that can transfer redox po-
tential between subcellular compartments and between
cells (Phang et al. 2001). PRODH was one of 14 genes
among 7,202 assayed in a cultured colorectal cancer
cell line whose expression was increased 10-fold by
p53-induced genes (p53) (Polyak et al. 1997). A similar
upregulation of PRODH by p53 was observed in a
bladder carcinoma cell line (Maxwell and Davis 2000).
Subsequent reports have shown that cells with high
PRODH expression demonstrate a proline-dependent
increase in reactive-oxygen species (ROS) generation,
suggesting that high POX activity with attendant in-
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Figure 1 Diagram of PRODH (upper panel) and WPRODH (lower panel). The exons, represented by the gray rectangles, are numbered
and shown roughly to scale. The intronic sequence is represented by the black heavy line and is not to scale. The exonic location of the missense
mutations, by exon, is shown above the rectangles. The translation start site in exon 2 is indicated by the right-angle arrow; the heavy dashed
line below the rectangles in the upper panel indicates the ∼10-kb PRODH-specific PCR product. The deletion in WPRODH is indicated by the
dashed lines in the lower panel.
Figure 2 Schematic representation of proline metabolic path-
ways. The rectangle represents a mitochondrion (see text for additional
details).
creases in ROS and/or the proline redox cycle may play
a role in apoptosis and/or cellular proliferation (Max-
well and Davis 2000; Donald et al. 2001; Maxwell and
Rivera 2003).
Proline itself has multiple physiological functions. It
is a nonessential, protein amino acid with a pyrrolidine
ring structure that provides unique characteristics for
peptide structure (Berg et al. 2002). Free proline is also
utilized as an osmolyte in certain plant and human cells
(Kiyosue et al. 1996; Yoshiba et al. 1997; Dall’Asta et
al. 1999; Takagi et al. 2000; Bussolati et al. 2001).
Additionally, several properties of proline metabolism
in the CNS suggest that proline functions as an inhib-
itory neurotransmitter and/or as a metabolic precursor
of glutamate in subpopulations of glutamatergic neu-
rons (reviewed in Phang et al. [2001]). Consistent with
this hypothesis, a specific, high-affinity proline trans-
porter (hProt/SLC6A7) has been shown to be expressed
in certain glutamatergic neurons, where it localizes to
the membranes of small, subsynaptic vesicles or, more
rarely, to the plasma membrane of these axon terminals
(Fremeau et al. 1992; Shafqat et al. 1995; Velaz-Fair-
cloth et al. 1995; Renick et al. 1999). Proline has also
been shown to be a regulator of cortical acetycholines-
terase activity in rats (Fremeau et al. 1992; Delwing et
al. 2003a, 2003b).
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Several defects in the proline catabolic pathway have
been associated with increased plasma proline levels
(fig. 2). Two monogenic, autosomal recessive inborn
errors are known. Hyperprolinemia type I (HPI [MIM
239500]) results from inherited deficiency of POX and
is associated with plasma proline levels with a range of
3–10-fold above normal (mean plasma proline in con-
trols after an overnight fast is 161 mM, with a range of
51–271 mM) (Phang et al. 2001). Hyperprolinemia type
II (HPII [MIM 239510]) results from inherited defi-
ciency of the second enzyme in the proline catabolic
pathway, P5C dehydrogenase, and is characterized by
plasma proline levels 10–15-fold above normal and ex-
cretion of P5C in urine (Valle et al. 1976; Geraghty et
al. 1998). The clinical phenotype of HPII includes an
increased frequency of seizures and mild mental retar-
dation (Flynn et al. 1989; Geraghty et al. 1998; Phang
et al. 2001). The phenotype of HPI is less well charac-
terized. Although many affected individuals have been
described as asymptomatic, a few with severe neurologi-
cal manifestations, including at least two with schizo-
phrenia, have been reported (Humbertclaude et al. 2001;
Jacquet et al. 2002, 2003). It is uncertain whether these
associations reflect pathophysiological consequences of
the metabolic disturbances in HPI or ascertainment bias.
Mild hyperprolinemia to an extent overlapping with
that of HPI has also been observed in VCFS/DGS, a
spectrum of developmental abnormalities that results
from a 1.5–3-Mb deletion in 22q11 (McDermid and
Morrow 2002). Prior to the mapping of PRODH, Jae-
ken et al. (1996) suggested that the hemizygous deletion
of PRODH might account for the hyperprolinemia they
observed in a patient with VCFS/DGS, and subsequent
studies have shown that about half of patients with
VCFS/DGS have hyperprolinemia (Goodman et al.
2000). Interestingly, patients with VCFS have a greatly
increased risk (∼20–30-fold) of psychiatric disorders,
particularly schizophrenia (Pulver et al. 1994; Kara-
yiorgou et al. 1995; Lindsay et al. 1995; Murphy et al.
1999; Ivanov et al. 2003; Williams et al. 2003c). Con-
sistent with this observation, several studies have mapped
susceptibility loci for schizophrenia to 22q11. In par-
ticular, Liu et al. recently reported association of certain
PRODH variants with increased susceptibility to schizo-
phrenia (Liu et al. 2002b). Moreover, the same group
described a sensorimotor-gating deficit, an endopheno-
type also observed in patients with schizophrenia, in the
POX-deficient Pro/Re mouse (Gogos et al. 1999).
At least 16 PRODH missense mutations have been
identified in patients with HPI (Jacquet et al. 2002),
schizophrenia (Jacquet et al. 2002; Liu et al. 2002b;
Williams et al. 2003b), unexplained hyperprolinemia
(W.-W. Lin, C.-A. Hu, D. Valle, J. Steel, unpublished
observations), and control subjects (Jacquet et al. 2002;
Liu et al. 2002b; Williams et al. 2003b). The functional
consequences of these missense mutations have been
inferred by evolutionary conservation of the altered resi-
due, but none have been tested directly. Here, we use
transient transfections into cells (CHO-K1-C9) lacking
endogenous POX activity, to determine the functional
consequences of these 16 PRODH missense mutations
singly or as haplotypes with multiple mutations on POX
activity.
Material and Methods
Reagents and Chemicals
We purchased restriction enzymes and buffers from
New England Biolabs: Pfu-Turbo DNA polymerase from
Stratagene and chemicals from Sigma. We obtained 14C-
proline from New England Nuclear and purified it prior
to use by ion-exchange chromatography on Dowex AG
50w-8x hydrogen form (BioRad) (Phang et al. 2001).
To assay green fluorescent protein (GFP) fluorescence,
we used a Zeiss LSM 510 Meta confocal laser-scanning
microscope.
Cloning and Mutagenesis of Human Proline Oxidase
Utilizing RT-PCR and the PRODH cDNA sequence
we previously submitted to GenBank (accession number
NM_016335), we cloned a full-length PRODH cDNA
and transferred the 2.4-kb EcoRI/KpnI fragment con-
taining the entire 1,800-bp ORF into pBluescript KS
(Stratagene). An alternative cDNA (GenBank accession
number AF120278) encodes an N-terminal truncated
protein lacking 84 N-terminal amino acids and recog-
nizable mitochondrial leader sequence and has not been
shown to encode a functionally active enzyme.
We created synonymous mutations that introduced a
ClaI (ATC GACrATC GAT) and a BstEII (GGC TAC
CCCrGGT TAC CCC) site at cDNA positions 966 and
1626, respectively (where 1 is the A of the initiation
methionine codon). This step allowed division of the
ORF into three fragments by use of restriction enzymes.
For expression, we transferred the wild-type PRODH
cDNA into pTracer (Invitrogen) by EcoRI/KpnI and
verified the integrity of the recombinant plasmid by se-
quencing. We mutagenized the ClaI/BstEII-modified
PRODH cDNA in pBluescript KS by PCR by use of the
QuikChange Mutagenesis Kit (Stratagene). All primers
are listed in a supplementary tab-delimited ASCII file
(online only), which can be imported into a Microsoft
Excel spreadsheet. Dependent on the position of the de-
sired mutation, we subcloned either the mutagenized
KpnI/ClaI or mutagenized ClaI/BstEII fragment into the
pTracer expression construct and resequenced to verify
the presence of the mutation and the integrity of the
ligations.
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Transfection and Assay of POX Activity
For all expression studies, we utilized a subclone
(CHO-K1-C9) of CHO-K1 cells that lack endogenous
POX activity (Valle et al. 1973). For electroporation, we
used 30 mg of the indicated plasmid DNA and 350 volts/
400 Q/960 mF in 300 ml of growth medium containing
1.25% DMSO and cells. After 48 h, we har-65–7 # 10
vested the cells by washing the monolayer with PBS and
scraping them into cold PBS. The cells were collected by
centrifugation at and were resuspended in 0.1480 # g
M KPO4 (pH 7.2). The cells and their organelles were
disrupted by sonication for 1 min at a setting of 25%
(Branson Sonifier 450 [Branson Ultrasonics]). Total pro-
tein was determined with the Pierce BCA protein assay
(Pierce). POX-specific activity (nmol/prod/mg/hr) was
assayed radioisotopically, as described elsewhere (Phang
et al. 1975). To account for variation in transfection
efficiency, we expressed the data as a percentage of wild
type (specific activity of mutant allele/transfection effi-
ciency)/(specific activity of wild-type allele/transfection
efficiency). For alleles with severe reduction in POX ac-
tivity, we repeated the assay with the addition of 1 mM
FAD.
Antibodies and Immunoblotting
We generated a rabbit anti-human POX antiserum
against a peptide corresponding to the exact C-terminus
of POX (-LLRRLRTGNLFHRPA) and used it in a dilu-
tion of 1:500. The secondary antibody, goat anti-rabbit
horseradish peroxidase, was used in a dilution of 1:5,000.
We used a mouse anti-GFP monoclonal antibody (Clon-
tech) to detect GFP. For immunoblotting, we separated
the proteins (20 mg/lane) by SDS PAGE and transferred
them to Hybond-PVDF membranes (Amersham), ac-
cording to the protocols of the manufacturer.
Genotyping
For those PRODH alleles whose frequency was not
available in the literature (A167V, D426N, Q521E, and
Q521R), we genotyped 50 North American controls.
Because these mutations are also present in WPRODH,
we used a long-range PCR strategy to selectively amplify
an ∼10-kb fragment present only in PRODH, using
primers that are not complementary to any WPRODH
sequence. This ensures that the genotyping reflects only
PRODH (Williams et al. 2003b). From this 10-kb frag-
ment, we amplified the individual exons and genotyped
by analysis with restriction enzymes or by hybridization
to allele-specific oligonucleotides (ASO), as described
elsewhere (Braverman et al. 1997). All primers, restric-
tion sites, and ASO probes are listed in the supplemen-
tary data file (online only).
Results
PRODH Alleles
The full-length PRODH cDNA (GenBank accession
number NM_016335) encodes a protein of 600 amino
acids with a putative N-terminal mitochondrial leader
sequence of 25 residues and a possible leucine zipper
domain between residues 79 and 100 (fig. 3). The C-
terminal 40% of the protein is highly conserved, with
12 blocks of identity of two or more amino acids across
representative eukaryotic species, human to yeast. More-
over, in the recently solved structure of the Escherichia
coli POX ortholog, PutA669 (Lee et al. 2003), 18 of the
40 residues that are within 5 A˚ of substrate or cofactor
are identical to the corresponding residues in the con-
served blocks in eukaryotic POX. Of the 16 missense
mutations we studied, 12 alter residues in this region of
the protein. The PRODH alleles expressed in this study
and their frequency and clinical associations are sum-
marized in table 1. Of the 16 mutations, 10 were poly-
morphic, with a frequency 0.01 in the general popu-
lation, in one or more studies.
POX Activity
The specific activity of POX measured in our transient
transfection assays could be influenced by transfection
efficiency and by level of expression of the introduced
recombinant plasmid. To control for the former, we
scored the fraction of cells expressing GFP in counts of
500 cells on cover slips included in the cell-culture dish.
Transfection efficiencies determined in this way had a
range of 12%–15% and were used to normalize the POX
activity. To control for the level of expression, we took
advantage of the fact that the pTracer vector used in
these studies expresses both GFP and the introduced
cDNA, which allowed comparison of the relative amounts
of GFP and POX in immunoblots on sonicates of the
transfected cells (fig. 4). In general, the relative amounts
of POX and GFP for each construct were similar, which
indicates that PRODH expression and POX stability
were the same for each of the mutant alleles. POX-
L441P is an exception, with reduced amounts as com-
pared with GFP, which suggests that this mutation re-
duces the stability of POX, an observation that agrees
with a recent report showing that the corresponding mu-
tation in E. coli PutA669 (L432P) results in an unstable
enzyme (Zhang et al. 2004). Despite this effect on sta-
bility, the amount of POX-L441P present in the soni-
cates (∼20% of control) was sufficient to assay its en-
zymatic activity. We also note reduced amounts of GFP
in sonicates of cells expressing POX-Q19P. The expla-
nation for this is uncertain, but, relevant to our studies
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Figure 3 Alignment of the predicted PRODH amino acid sequences from various eukaryotic species. Residues conserved across three or
four of the sequences are indicated by a gray background, those conserved in all five eukaryotic examples by a black background. Also shown
are the 40 residues of E. coli PutA669 that are within 5 A˚ of substrate and/or cofactor (Lee et al. 2003). These are spaced as they are in
PutA669, but, for the sake of clarity, we have not shown the intervening residues. The shading scheme for the E. coli residues follows the
convention for the eukaryotic sequences. The locations of the human missense mutations studied in this article are indicated at the top of the
figure. The arrowhead indicates the predicted cleavage site for the mitochondrial targeting sequence. The overline indicates a possible leucine
zipper motif. HspHomo sapiens, MmpMus musculus, DmpDrosophila melanogaster, CepCaenorhabditis elegans, ScpSaccharomyces cer-
evisiae, and EcpE. coli.
of POX activity, the amount of POX-Q19P is similar to
that of the other mutant forms of POX (fig. 4).
The normalized POX activity encoded by the PRODH
alleles in our study varied widely (fig. 5). For purposes
of analysis, we grouped the alleles into three categories
by activity: group I contains four alleles (R185Q, L289M,
A455S, and A472T) with little, if any, effect on POX
activity (!30% reduction); group II contains six alleles
(Q19P, A167V, R185W, D426N, V427M, and R431H)
with moderate (30%–70%) reduction of POX activity;
and group III contains five alleles (P406L, L441P, R453C,
T466M, and Q521E) with severe (170%) reduction in
POX activity. Interestingly, one allele, O521R, encodes
a POX with increased activity (120% of wild type).
Because some of the PRODH mutations were de-
scribed on haplotypes with others, we also expressed
three PRODH alleles with two or three missense mu-
tations in cis (L441P/R453C, V427M/R431H/L441P,
and R453C/T466M/A472T) (Humbertclaude et al. 2001;
Jacquet et al. 2002; Liu et al. 2002b). Each of these
haplotypes has at least one missense mutation that, in
isolation, confers severe reduction of POX activity. We
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Table 1
Analysis of PRODH Alleles
Allele
Reference
SNP (rs)
Number Exon
Allele Frequency
in Control Individualsa Identified inb
Associated
with
Schizophreniac
Q19P 2008720 2 .29d C, S
A167V 4 .03e C, S
R185W 4819756 5 .37f C, S
R185Q 5 .05f C
L289M 8 .03f; 0/136g C, H, S
P406L 3970555 11 0/216f S
D426N 12 0/94e H
V427M 2238731 12 .02f C, H, S f
R431H 2904552 12 .16d; .10g; .13h C, H, S
L441P 2904551 12 0/74f; 0/136g H, S
R453C 3970559 12 .004f; .015g C, H, S f
A455S 1807467 12 0/136g H, S
T466M 2870984 12 0/156f S f
A472T 2870983 12 .02f; .10g; .07h C, S f
Q521R 450046 14 .05g C, H, S
Q521E 14 0/94e
a Frequency in controls, as determined by the indicated (footnoted) study. For alleles not
detected, the result is presented as 0/number of chromosomes screened.
b Cpcontrol individuals, Hphyperprolinemics, and Spschizophrenics.
c Associated with schizophrenia in at least one study, at .P  .05
d Williams et al. 2003b.
e The present study.
f Liu et al. 2002.
g Jacquet et al. 2002.
h Jacquet et al. 2004.
found the POX activity encoded by these haplotype al-
leles was dictated by the functionally most-severe mis-
sense mutation with no evidence of intra-allelic com-
plementation (Turner et al. 1997; Walker et al. 1997).
POX Activity of Severe Mutants Measured under High
FAD Conditions
Our standard POX assay depends on FAD already
bound to the apoenzyme (Phang et al. 1975). To check
for alleles with altered cofactor affinity, we also assayed
all five group III alleles in the presence of supplementary
FAD (1 mM). Four of these alleles showed little or no
response, but one, T466M, showed a 3–4-fold increase
in activity, from 5%–10% to 30–40% of control. Struc-
tural considerations based on the structure of E. coli
PUTA669 suggest that T466 of POX interacts with the
adenine moiety of FAD to stabilize the noncovalent bind-
ing of the cofactor to the POX apoenzyme. Thus,
T466M would be expected to alter the affinity of the
POX apoenzyme for FAD. To test this expectation, we
assayed POX activity over a range of added FAD con-
centrations (5–1,000 mM) in partially purified mito-
chondrial extracts of CHO-K1-C9 cells transfected with
either wild-type or T466M PRODH. From these results,
we estimated the Km for FAD of wild-type POX to be
∼ and that of T466M-POX to be ∼90.25 # 10 3 #
, or at least 1 order of magnitude higher (data not910
shown).
Discussion
The extent of polymorphism and its consequences varies
considerably from gene to gene across the genome (Car-
gill et al. 1999; Halushka et al. 1999; Reich and Lander
2001). PRODH is toward the high end of this spectrum,
with several recognized variants that occur at polymor-
phic frequency (10.01). This high rate of polymorphism
appears to result, at least in part, from the existence of
a nonprocessed pseudogene 1.4 Mb telomeric on chro-
mosome 22 that serves as a reservoir of variation that
can be transferred to PRODH by gene conversion. A
similar mechanism is thought to explain the high fre-
quency of polymorphism in CYP21A2, which encodes
a key enzyme in steroid hormone biosynthesis and has
a nearby pseudogene (CYP21A1P) in 6p21 (Donohoue
et al. 2001).
To test the functional consequences of the polymor-
phic and rare variant PRODH alleles, we expressed all
16 known PRODH missense mutations individually and,
in some instances, as haplotypes with multiple muta-
tions in cis. Among these 16 missense mutations, we
found 4 that result in a mild (30%) (group I), 6 that
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Figure 4 Immunoblot analysis of POX and GFP in sonicates of
cells transfected with the indicated recombinant pTracer construct. For
each panel, POX is shown above, GFP below. Each lane contains 20
mg of crude cell sonicate. POX migrates as an ∼66-kDa protein.
result in a moderate (30%–70%) (group II), and 5 that
result in severe (170%) (group III) reduction in POX
activity. There was a rough but imperfect correlation
between allele frequency and effect on activity: the 10
polymorphic alleles included 4 in group I, 5 in group
II, and only 1 (E453C) in group III. By contrast, of the
six rare PRODH alleles, four encoded POX with a se-
verely reduced activity (group III), with only one each
in groups I and II. This correlation would be consistent
with a selective disadvantage against the functionally
severe alleles, but additional population-genetics studies
would be necessary to confirm this suggestion. Inter-
estingly, one polymorphic mutation (Q521R) with an
allele frequency of ∼0.05 encoded an enzyme with an
activity ∼20% higher than that of the common Q521
allele (fig. 5).
One caveat regarding our results is that the POX
activity we measure reflects the catalytic activity and
stability of the holoenzymes that result from expression,
targeting, and assembly of POX subunits encoded by
the expressed cDNAs. Our experiments circumvent any
additional effects these mutations might have on splic-
ing or RNA stability (Cartegni et al. 2002). In particular,
a mutation that has only a mild effect on POX activity
in our experiments could have a profound effect on
POX activity in vivo by alteration of splicing. Testing
for this would require RT-PCR analysis in expressing
tissues in individuals of known genotypes. As a proxy
for this, we analyzed our set of PRODH missense mu-
tations with the online analysis tool ESEfinder (2.0) to
search for mutations predicted to alter exon-splice en-
hancers (Cartegni et al. 2003). Q19P in exon 2 was the
only mutation in our mild or moderate categories
(groups I and II) predicted to alter a splice enhancer.
Interestingly, the 3′ splice site in intron 1 has a weak
polypyrimidine tract (ggcgggaccaacag/C… vs. the con-
sensus of (t/c)10 n c/tag/G …) (Shapiro and Senapathy
1987), which suggests the possibility that exon 2 utilizes
a splice enhancer (Cartegni et al. 2002). Additional
studies of individuals of this genotype will be required
to address this possibility.
Ideally, our observations on the functional conse-
quences of these 16 missense mutations on POX activity
would be understood in the context of the three-di-
mensional structure of human POX. Although this is
not available, the structure of the POX segment (resi-
dues 1–669, designated “PutA669”) of the multifunc-
tional 1,320 residue PutA enzyme of E. coli was recently
described (Lee et al. 2003). PutA669 binds FAD, has
the POX activity of the full-length protein, and has the
overall structure of an interlocking homodimer (Lee et
al. 2003; Zhang et al. 2004). Each PutA669 subunit has
three domains: domain I (residues 87–139) forms an
arm reaching out from one subunit to partially encircle
the other, domain II (residues 140–260) does not contact
the other subunit or make contributions to the active
site and has unknown function, and domain III (residues
261–612) forms a b8a8 barrel that binds FAD and per-
forms the proline oxidase function of PutA669. Al-
though a sequence comparison of PutA669 and human
POX over residues 341–570 of the human enzyme shows
an amino acid identity of only 15%, this increases to
47% for the 40 human POX residues that correspond
to putA669 residues within a 5-A˚ neighborhood of sub-
strate and/or cofactor. On the basis of the high level of
sequence identity of these critical residues and of the
common catalytic function, Lee et al. (2003) argue that
PutA669 and human POX share a common active site
and that the structure of the human protein can be mod-
eled on PutA669.
The model predicts that human POX residues 341–
570 form a b8a8 barrel structure. Three of the five mu-
tations with a severe effect on POX activity (group III)
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Figure 5 Proline oxidase activity of PRODH alleles. For each transfected allele, the activity was normalized to transfection efficiency
and was expressed as a percentage of the wild-type allele (see the “Material and Methods” section). The thin vertical lines indicate the range
of mean activity measured in two-to-five independent transient transfection experiments. Bars without these vertical lines indicate the mean of
a triplicate assay performed in one transfection experiment. For some alleles (L441P, R453C/T466M, and A472T), the value is from multiple
experiments, but the variance is so narrow that it cannot be seen on this scale.
are in PRODH exon 12. The segment of POX encoded
by this exon (residues 418–477) forms an alpha helix
(a4), a beta strand (b5), and a helix-turn-helix structure
(a5a/a5). In putA669, b5 stabilizes proline binding, and
a5a is important for FAD binding (Dym and Eisenberg
2001; Lee et al. 2003). FAD is composed of an adeno-
sine monophosphate (AMP) connected by a pyrophos-
phate bond to flavin mononucleotide. The latter has an
isoalloxazine-flavin ring structure connected to a ribitol
group that, in turn, links to the pyrophosphate. The
binding of FAD to its resident apoenzyme typically in-
volves high affinity, noncovalent interactions with the
ribityl phosphate and AMP moieties of the cofactor,
whereas the catalytic function is concentrated in the
isoalloxazine ring (Dym and Eisenberg 2001). Two
group III mutations (L441P and Q521E) and the mu-
tation with increased activity (Q521R) alter b5 and would
be expected to affect the active site of POX, whereas a
third group III mutation, T466M in a5a, would be ex-
pected to alter FAD binding (fig. 6). L441P probably
disrupts the stabilizing interaction of V442 with the
isoalloxazine of FAD, adversely affecting the interaction
of substrate and cofactor (fig. 6). In fact, Zhang et al.
(2004) recently showed that the equivalent mutation in
PutA669 (L432P) results in a protein with significantly
lower catalytic activity and stability. They found a 5-
fold reduction in Kcat with no significant effect on Km
but a markedly reduced thermostability (Zhang et al.
2004)
The contrasting effects of the Q521R/E substitutions
(120% and 20% activity, respectively) can also be un-
derstood from the predicted structure of POX. The
PutA669 residue corresponding to Q521 (L513) con-
tributes to one wall of the active site and is located only
3.6 A˚ from proline, near the isoalloxazine end of FAD.
Q521R substitutes a basic residue that appears to en-
hance catalytic activity, whereas Q521E substitutes an
acidic residue for a polar neutral one and probably alters
the architecture of the active site, with severe reduction
of POX activity as the result.
To our knowledge, PRODH-T466M is only the sec-
ond example of an FAD-responsive mutation in hu-
mans. The other is the N324S allele of the methylene-
tetrahydrofolate reductase gene (MTHFR), which en-
codes the other b8a8 barrel FAD-binding protein whose
structure has been solved (Sibani et al. 2003). The
PutA669 residue corresponding to human T466 (R458)
is only 3.1 A˚ from the adenine group of FAD. Since this
end of FAD usually participates in the noncovalent bind-
ing of the cofactor to the apoenzyme, we speculated
that T466M destabilizes this interaction. To test this
hypothesis, we assayed T466M and all other mutant
POX enzymes with a severe reduction in activity in the
presence of high (1 mM) FAD. Of these, only T466M
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Figure 6 Structural models of the active site of human POX, as predicted from the solved structure of E. coli PutA669 (Lee et al. 2003).
The location of residues altered in certain of the missense mutations is shown: A, T466M; B, Q521E; C, L441P. The white arrows indicate
potential disruptive forces.
showed a significant response with a 3–4-fold increase
in activity to levels that are ∼30% that of control. Using
partially purified, mitochondrial preparations from cells
expressing either T446M or wild-type POX, we found
that T466M increases the Km for FAD at least 10-fold,
from ∼0.25 nM to 3 nM. It would be interesting to test
for riboflavin responsiveness in individuals carrying the
T466M-PRODH allele (Liu et al. 2002b).
How does the POX function of the various PRODH
alleles relate to biochemical and clinical phenotypes?
HPI, an autosomal recessive inborn error, was shown
to be due to inherited deficiency of POX, in classic bio-
chemical studies by Efron, Scriver, Schafer, and their
colleagues in the 1960s (Scriver et al. 1961; Schafer et
al. 1962; Efron 1965). Because PRODH expression is
limited to tissues that are not readily accessible (liver,
kidney, and brain), there have been almost no additional
studies of POX activity in this disorder. Consequently,
HPI has been a diagnosis of exclusion (chronic hyper-
prolinemia without excretion of P5C and with normal
P5C dehydrogenase activity in lymphoblasts or fibro-
blasts). Although the data are limited, it is possible to
combine our results on the POX activity encoded by
the various PRODH alleles and plasma proline levels
published by others to begin to relate genotype to meta-
bolic phenotype. One patient with HPI, homozygous
for a 350-kb deletion that removed the entire PRODH
gene, had a proline level of 2,246 mM (Jacquet et al.
2003). Two patients who were homozygous for the most-
severe missense mutation (L441P), with essentially un-
detectable activity in our assay, had proline levels of
1,255 mM and 800 mM (Jacquet et al. 2002). A com-
pound-heterozygote patient with a PRODH deletion
and missense allele with low but detectable residual ac-
tivity (R453C; 9% activity) had a level of 538 mM (Jac-
quet et al. 2002). At the low end of the spectrum of
elevated plasma proline (300–500 mM), the situation is
much less clear, and several individuals appear to be
heterozygous for alleles with a range of residual activity.
Interestingly, Scriver, on the basis of family studies,
pointed out many years ago that some individuals pre-
dicted to be heterozygous for an HPI allele had mild
but significant hyperprolinemia (Scriver 1978). Although
many variables—including dietary intake, metabolic
state, and drugs—influence plasma proline levels, the
emerging picture suggests that there is a broad “dy-
namic range” in the relationship between POX activity
and plasma proline levels. In their classic studies, Kacser
and Burns (1981) predicted that this would be the case
for enzymes catalyzing the initial step in a pathway, as
compared with those catalyzing intermediate steps in a
pathway. The latter have more opportunity for meta-
bolic buffering provided by the multiple steps in the
pathway, each with substrate pools. Much work needs
to be done to relate PRODH genotype and residual
POX activity to plasma proline levels and, more im-
portantly, to proline accumulation in key local envi-
ronments in the CNS.
The clinical phenotype of HPI is not as well under-
stood as the metabolic phenotype. Some individuals with
HPI have been described as “normal,” others have had
neurological abnormalities, and at least two received a
diagnosis of schizophrenia (Jacquet et al. 2002). It
would be important to restudy these individuals, to de-
termine if their phenotypes were typical of schizophre-
nia or if, in retrospect, there were any unusual features
(age at onset, response to therapy, etc.).
PRODH variants have also been implicated as sus-
ceptibility factors for schizophrenia and schizoaffective
disorder in some (Gogos et al. 1999; Chakravarti 2002;
Jacquet et al. 2002, 2004; Liu et al. 2002b; Hoogen-
doorn et al. 2004; Li et al. 2004) but not all studies
(Williams et al. 2003a, 2003b; Ohtsuki et al. 2004). To
account for increased susceptibility for a common phe-
notype, a locus must have a substantial reservoir of varia-
tion (Reich and Lander 2001; Pritchard and Cox 2002),
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and this is the case for PRODH (see table 1). Moreover,
a role for PRODH variants is consistent with the well-
documented 20–30-fold increase in risk of schizophre-
nia in patients with VCFS/DGS due to 22q11.2 deletions
that include the PRODH locus (Shprintzen et al. 1992;
Pulver et al. 1994; Karayiorgou et al. 1995; Murphy et
al. 1999). The psychiatric phenotype of these individ-
uals has been described either as indistinguishable from
that of schizophrenic patients without 22q11.2 dele-
tions (Bassett et al. 2003) or as having a later onset and
fewer negative symptoms (Murphy et al. 1999). Our
results indicate that nine functionally significant mu-
tations (130% reduction of POX activity) have been
found in the PRODH genes of patients with schizo-
phrenia. Moreover, we find that three of four alleles
shown elsewhere to be significantly associated with
schizophrenia encode POX with !30% of normal ac-
tivity. The fourth allele, A472T, encodes an enzyme with
70% activity. True positive associations of a phenotype
with a particular variant may occur because the variant
is the causative mutation or because the variant is in
linkage disequilibrium with the causative mutation (Page
et al. 2003). Thus, the association with A472T could
reflect an increase in risk conferred by a modest reduc-
tion in POX activity or could reflect linkage disequilib-
rium of A472T with a more severe, as-yet-undetected
variant. A role for reduced POX function as a risk factor
for schizophrenia is consistent with the results of Jac-
quet et al., who identified two schizophrenic patients
with HPI (Jacquet et al. 2002) and found that hyper-
prolinemia is a significant risk factor ( ) for theP p .02
related phenotype, schizoaffective disorder (Jacquet et al.
2004). Additionally, the observation of sensorimotor-
gating abnormalities in the POX-deficient Pro/Re mouse
support a role for reduced POX activity as a risk factor
for schizophrenia (Gogos et al. 1999).
Unfortunately, we know little about the relationship
of proline concentrations in plasma and CNS, particu-
larly in the subpopulations of glutamatergic neurons for
which proline has been proposed to function as a neu-
rotransmitter or as a modulator of neurotransmission
(Renick et al. 1999). Variation in proline metabolism is,
however, an attractive candidate risk factor for schizo-
phrenia. Because POX is expressed in the CNS and cata-
lyzes the first step in the catabolic pathway that converts
proline to glutamate, variation in POX activity has the
potential to influence both proline and glutamate levels
in CNS. Perturbation of the proline/P5C redox shuttle
also could influence the metabolic activity and/or ap-
optosis in selected neurons. Taken together, our results
and these considerations indicate that further studies
of proline metabolism and function in the CNS are
warranted.
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